Joint with AIChE
"Challenges in the Large Scale Synthesis of Potent Drugs"
Sr. Program Manager
"Design and Engineering for the Global R&D Development
Center of Oral Dosage Forms"
Date: Wednesday, February 8, 2006 - note Wednesday, not Friday. Location: Abbott Laboratories
10th Street & Sheridan Road
North Chicago, IL 60064
Cost: $28.00 for members of ACS and their guests, $30.00 for non-members,
$14 for students or unemployed
Dinner reservations are required and should be received in the Section Office via phone (847-647-8405), fax (847-647-8364), email (firstname.lastname@example.org), or web by noon on Wednesday, February 1. Note the early reservation cut-off date. No walk-ins will be permitted. Registration is a must!! PLEASE HONOR YOUR RESERVATIONS. The Section must pay for all dinner orders. No-shows will be billed.
Please REGISTER ON LINE
5:00 - 6:45 Tours - Tours of Abbott's High Potency Drug Facility are available. The number of tours is limited and will be given on a first-come basis. Arrive early!
5:00 - 6:30 PM Social Hour
5:30 - 6:30 PM Job Club
6:30 PM Dinner
7:30 PM Program
There will be two speakers, Howard Morton (pictured) and David McAlonan, both of Abbott Labs. They will provide insight into the development and manufacturing of potent drugs. Potent drugs are compounds where the daily dose is 10mg or less. The challenge in handling potent compounds is to do so effectively without ingesting a dose.
Dr. Howard Morton, Director of Process Chemistry, Abbott Laboratories
Biography: Dr. Howard Morton received his B.S. degree in Honors Chemistry at the University of British Columbia in 1976. He continued there for his graduate work with Professor Edward Piers developing the first useful trialkyltin-cuprate reagents for organic synthesis obtaining his Ph.D. in 1981. After starting his career in Pharmaceutical Research at Merck Frosst, he joined the Abbott Laboratories Process Chemistry group in 1988 as a Senior Research Chemist. There he has distinguished himself in developing novel and efficient chemical reactions applicable to Abbott's clinical candidates.
Howard is the inventor and co-inventor of processes directed towards: Renin Inhibitors; HIV Protease Inhibitors - Ritonovir and Lopinavir; PAF Antagonists; and Oncolytics among others. Currently he is Director of Process Chemistry at Abbott Laboratories. He has authored and co-authored more than 60 scientific papers and patents and has served as a member of the Organic Process Research and Development Editorial Advisory Board.
Dave McAlonan, Sr. Program Manager, Global Engineering Services, Abbott Laboratories
Biography: David McAlonan is a Senior Program Manager in Global Engineering Services for Abbott Laboratories located in Abbott Park, Illinois. He has a B.S. degree in Chemical Engineering and has more than 30 years of professional experience developing and implementing projects primarily in the chemical and pharmaceutical industries.
David has been with Abbott Laboratories for about 20 years holding several positions in Operations Management, Project Management and Program Development. Over the past four years, his main focus has been in the development of a Potent Drug Containment Program for the Global Pharmaceutical Research & Development division. This program is made up of about 20 projects over a five-year period to implement potent drug containment projects within R&D on a scale up basis from laboratory scale (under 1 kilogram) to pilot plant facilities (up to 75 kilograms) and address the tech transfer to commercial facilities beginning with a 300 kilo scale. This program involves both API and final drug compounding for clinical deliveries.